Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Tuesday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright lowered their price target on Aethlon Medical from $10.00 to $7.00 and set a buy rating for the company in a research report on Monday, June 24th.

Aethlon Medical Stock Performance

AEMD opened at $0.38 on Tuesday. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $2.35. The company’s 50 day simple moving average is $0.40 and its 200 day simple moving average is $0.66. The stock has a market capitalization of $5.25 million, a PE ratio of -0.08 and a beta of 1.74.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.10. During the same quarter last year, the business posted ($1.30) earnings per share. As a group, sell-side analysts expect that Aethlon Medical will post -1.1 earnings per share for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.